Neoadjuvant chemotherapy: Not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?

Journal of Clinical Oncology

Volumn 28, Issue 22, 2010, Pages 3552-3554

  Purushotham, Arnie ^a   Pinder, Sarah ^a   Cariati, Massi ^b   Harries, Mark ^a   Goldhirsch, Aron ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; TAMOXIFEN; ESTROGEN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; APOPTOSIS; BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL PROLIFERATION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; LUNG CARCINOMA; NOTE; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; FEMALE; METABOLISM; NEOPLASM;

BREAST NEOPLASMS; CARCINOMA, LOBULAR; ESTROGENS; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 77955885755     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.8184     Document Type: Note

References (22)

1. Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127-2137, 1992
2. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102, 2001
3. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997 (Pubitemid 27289876)
4. Mauri D, Pavlidis N, Ioannidis JP: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 97:188-194, 2005 (Pubitemid 40277368)
5. Farese SA, Aebi S: Infiltrating lobular carcinoma of the breast: Systemic treatment. Breast Dis 30:45-52, 2009
6. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al: Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41-48, 2005 (Pubitemid 41702621)
7. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, et al: Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: A retrospective study on 860 patients from one institution. Ann Oncol 17:1228-1233, 2006 (Pubitemid 44288213)
8. Katz A, Saad ED, Porter P, et al: Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 8:55-62, 2007 (Pubitemid 44943091)
9. Soucy G, Bélanger J, Leblanc G, Sideris L, et al: Surgical margins in breast-conservation operations for invasive carcinoma: Does neoadjuvant chemotherapy have an impact? J Am Coll Surg 206:1116-1121, 2008
10. Boughey JC, Wagner J, Garrett BJ, et al: Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol 16:1606-1611, 2009
11. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 12:1527-1532, 2001 (Pubitemid 34065880)
12. Ellis MJ, Ma C: Letrozole in the neoadjuvant setting: The P024 trial. Breast Cancer Res Treat 105:33-43, 2007 (suppl 1) (Pubitemid 47524802)
13. Smith IE, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108-5116, 2005 (Pubitemid 46224019)
14. Cataliotti L, Buzdar AU, Noguchi S, et al: Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106:2095-2103, 2006
15. Arpino G, Bardou VJ, Clark GM, et al: Infiltrating lobular carcinoma of the breast: Tumor characteristics and clinical outcome. Breast Cancer Res 6:R149-R156, 2004
16. Pestalozzi BC, Zahrieh D, Mallon E, et al: Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26:3006-3014, 2008
17. Bertucci F, Orsetti B, Nègre V, et al: Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 27:5359-5372, 2008
18. Weigelt B, Geyer FC, Natrajan R, et al: The molecular underpinning of lobular histological growth pattern: A genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 220:45-57, 2010
19. Fadare O, Wang SA, Hileeto D: The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: Evidence of a basal-like subset? Hum Pathol 39:331-336, 2008
20. Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, et al: Biologic markers in axillary node-negative breast cancer: Differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer 7:396-400, 2006 (Pubitemid 46157560)
21. Goldstein NS, Decker D, Severson D, et al: Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 110:1687-1696, 2007 (Pubitemid 47557293)
22. Vargas AC, Lakhani SR, Simpson PT: Pleomorphic lobular carcinoma of the breast: Molecular pathology and clinical impact. Future Oncol 5:233-243, 2009